Top

Reactions Weekly

Published in:

01-12-2023 | Diffuse Large B-Cell Lymphoma | Case report

Lenalidomide/rituximab/agammaglobulinaemia-tyrosine-kinase-inhibitors

Rash

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Jiang P, et al. BTK Inhibitors in Combination with Rituximab and Lenalidomide (BTKiR2) for Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: A Single-Center Prospective Study in China. Blood 140 (Suppl. 1): 9487-9488, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-159588 [abstract]

Title: Lenalidomide/rituximab/agammaglobulinaemia-tyrosine-kinase-inhibitors
Rash
Publication date: 01-12-2023
Publisher: Springer International Publishing
Keywords: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Rituximab
Rituximab
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51542-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lenalidomide/rituximab/agammaglobulinaemia-tyrosine-kinase-inhibitors

Rash

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

ADHD medication: long-term risk of cardiovascular disorders

Severe-acute-respiratory-syndrome-coronavirus-2-mrna-vaccine

Catequentinib/osimertinib

Multiple drugs

Levomepromazine/quetiapine

Pembrolizumab